healthfinch to grow with $7.5M in Series A funding

healthfinch, the healthcare IT company behind the award-winning application Swoop for prescription refill requests, has secured $7.5 million in Series A financing to build out its practice automation platform, “Charlie.”

Investment firm Adams Street Partners led the round, with participation from JumpStart Ventures, Chicago Ventures, OCA Ventures, Abundant Ventures and a private investor. This financing round brings healthfinch’s total raise to over $10 million since CEO Jonathan Baran, MS, and CMO Lyle Berkowitz, MD, founded the company in 2011.

“The rapid adoption and demand from health systems for Swoop is a clear indication that automating routine and repeatable tasks is the future of healthcare delivery,” said Baran in a release. “To this end, we’re moving beyond individual applications in favor of a robust practice automation platform that can handle many more tasks beyond prescription refill requests including visit planning, patient communication and much more.”

Tom Bremner, a partner at Adams Street, cited healthfinch’s “winning trifecta” of “strong clinical and executive leadership, a compelling product roadmap that will bring clear value to the healthcare system, and most importantly, clients who have been using healthfinch products to achieve up to 5 times efficiency and financial ROI.”

The Series A funds will be used to augment healthfinch’s technical and clinical teams to accelerate development of the Charlie platform and expedite delivery to health systems, according to Baran.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.